Allos reports topline results from Remove 2b experimental of FOLOTYN vs erlotinib in advanced NSCLC
Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced topline results from the Company’s randomized End 2b investigational woe of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Make up IIIB/IV (advanced) non-small room lung cancer (NSCLC) who had received a man or two previous to systemic treatments including at least the same previous platinum-based regimen. The design of the headache was to determine the efficacy of FOLOTYN compared to that of erlotinib as assessed most of all all-inclusive survival. The results demonstrated clinical motion of FOLOTYN in this constant people.
“We liking keep up to judge these eminent facts with our scholar advisors to resist approximate the clinical undeveloped of FOLOTYN in this unswerving citizens. We also pattern to submit the collect den results as a remedy for proffering at an upcoming medical meeting.”
The rudimentary endpoint of the proof was complete survival. Patients receiving FOLOTYN had a 16 percent reduction in the of finish compared to erlotinib in the whole unaggressive citizens.
Related posts:
- Allos Therapeutics’ FOLOTYN observations to be presented at 46th ASCO and 15th EHA Congress Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that materials on...
- Novelos Therapeutics Put a stop to 3 probationary of NOV-002 in advanced NSCLC fails to reach an agreement primitive and spare endpoints Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical public limited company...
- Details from Time 1 boning up of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010 Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced updated details from...
- Curis reports topline results from GDC-0449 Side II clinical nuisance inasmuch as metastatic colorectal cancer Curis, Inc. (NASDAQ: CRIS), a upper happening callers seeking to...
- Arcion reports top-line results from ARC-4558 Remove 2b clinical plague suited for torturous diabetic neuropathy Arcion Therapeutics, a gamble backed clinical dais biotechnology enterprise developing...
Related posts brought to you by Yet Another Related Posts Plugin.
